- Poster presentation
- Open Access
Regadenoson stress induced wall motion abnormalities during cardiac MRI
© Parikh et al; licensee BioMed Central Ltd. 2015
- Published: 3 February 2015
- Coronary Artery Disease
- Late Gadolinium Enhancement
- Wall Motion Abnormality
- Invasive Coronary Angiography
Wall motion abnormalities are central to dobutamine stress CMR but have not been studied with regadenoson. This study was designed to compare the diagnostic performance of regadenoson regional wall motion abnormalities (RWMA) versus first-pass perfusion in the detection of significant coronary artery disease (CAD).
Patients underwent regadenoson CMR that included 3 (basal, mid, apical) slices of rest and peak stress real-time cines, with matching stress and rest first-pass perfusion, and late gadolinium enhancement (LGE) imaging.
The reference standard for presence or absence of CAD was derived from invasive coronary angiography or coronary CT angiography (CTA). Invasive angiography established significant CAD based on a threshold of ≥70% stenosis and could rule-in or exclude CAD. CTA was only used to exclude CAD if the calcium score was <100 and no stenosis was >30%; CT was not used to diagnose CAD.
Two blinded, readers qualitatively scored RWM of pre and post-regadenoson.
26 of 49 patients had at least one 70% coronary artery stenosis. The sensitivity and specificity of regadenoson perfusion for detecting significant CAD was 92 and 91%, respectively. In comparison, the sensitivity and specificity of RWMA on stress imaging was 58 and 96%, respectively, and a new or worsening RWMA on stress compared to rest yielded a sensitivity and specificity of 38 and 100%, respectively. The sensitivity and specificity of LGE was 65 and 87%, respectively. Inter-reader agreement for RWMA was good (kappa 0.63).
Although sensitivity is poor, a regadenoson-induced wall motion abnormality seen on CMR likely indicates significant CAD.
Comparison of diagnostic accuracy of differing stress CMR exam components
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.